Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review

Linda Nguyen,1,2 Patrick J Marshalek,2 Cory B Weaver,1 Kathy J Cramer,2,3 Scott E Pollard,2,4 Rae R Matsumoto1,2,5 1Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, USA; 2Department of Behavioral Medicine and Psychiatry, School of Medicin...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Nguyen L, Marshalek PJ, Weaver CB, Cramer KJ, Pollard SE, Matsumoto RR
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d5110dc8f8654002a7f54f4727ea939c
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5110dc8f8654002a7f54f4727ea939c
record_format	dspace
spelling	oai:doaj.org-article:d5110dc8f8654002a7f54f4727ea939c2021-12-02T11:02:44ZOff-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review1178-2021https://doaj.org/article/d5110dc8f8654002a7f54f4727ea939c2015-10-01T00:00:00Zhttps://www.dovepress.com/off-label-use-of-transmucosal-ketamine-as-a-rapid-acting-antidepressan-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Linda Nguyen,1,2 Patrick J Marshalek,2 Cory B Weaver,1 Kathy J Cramer,2,3 Scott E Pollard,2,4 Rae R Matsumoto1,2,5 1Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, USA; 2Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, USA; 3Doctor of Nursing Practice Program, Robert Morris University, Moon Township, PA, USA; 4Department of Behavioral Health, West Park Hospital, Cody, WY, USA; 5College of Pharmacy, Touro University California, Vallejo, CA, USA Objective: This study evaluated the effectiveness and safety of subanesthetic doses of ketamine using an off-label, transmucosal administration route in patients with treatment-resistant depression.Methods: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant major depressive disorder. Seventeen such patients who received subanesthetic doses of ketamine were included. Patient demographics, efficacy (drug refill, clinician notes), side effects, and concurrent medications were assessed.Results: Benefit from low-dose transmucosal ketamine was noted in 76% of subjects (average age 48 years, 88% female), with a dose duration lasting 7–14 days. No notable side effects were noted. The most common classes of concurrent medications to which ketamine was added were serotonin–norepinephrine reuptake inhibitors (59%), stimulants (47%), folate replacement (47%), and benzodiazepines (47%).Conclusion: Our results provide preliminary evidence of the effectiveness and safety of low-dose transmucosal ketamine in treatment-resistant patients. A controlled, prospective pilot study is warranted to validate these findings. Keywords: ketamine, depression, treatment resistance, NMDA receptor, glutamate, mood disorder Nguyen LMarshalek PJWeaver CBCramer KJPollard SEMatsumoto RRDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2015, Iss default, Pp 2667-2673 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Nguyen L Marshalek PJ Weaver CB Cramer KJ Pollard SE Matsumoto RR Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
description	Linda Nguyen,1,2 Patrick J Marshalek,2 Cory B Weaver,1 Kathy J Cramer,2,3 Scott E Pollard,2,4 Rae R Matsumoto1,2,5 1Department of Pharmaceutical Sciences, School of Pharmacy, West Virginia University, Morgantown, WV, USA; 2Department of Behavioral Medicine and Psychiatry, School of Medicine, West Virginia University, Morgantown, WV, USA; 3Doctor of Nursing Practice Program, Robert Morris University, Moon Township, PA, USA; 4Department of Behavioral Health, West Park Hospital, Cody, WY, USA; 5College of Pharmacy, Touro University California, Vallejo, CA, USA Objective: This study evaluated the effectiveness and safety of subanesthetic doses of ketamine using an off-label, transmucosal administration route in patients with treatment-resistant depression.Methods: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant major depressive disorder. Seventeen such patients who received subanesthetic doses of ketamine were included. Patient demographics, efficacy (drug refill, clinician notes), side effects, and concurrent medications were assessed.Results: Benefit from low-dose transmucosal ketamine was noted in 76% of subjects (average age 48 years, 88% female), with a dose duration lasting 7–14 days. No notable side effects were noted. The most common classes of concurrent medications to which ketamine was added were serotonin–norepinephrine reuptake inhibitors (59%), stimulants (47%), folate replacement (47%), and benzodiazepines (47%).Conclusion: Our results provide preliminary evidence of the effectiveness and safety of low-dose transmucosal ketamine in treatment-resistant patients. A controlled, prospective pilot study is warranted to validate these findings. Keywords: ketamine, depression, treatment resistance, NMDA receptor, glutamate, mood disorder
format	article
author	Nguyen L Marshalek PJ Weaver CB Cramer KJ Pollard SE Matsumoto RR
author_facet	Nguyen L Marshalek PJ Weaver CB Cramer KJ Pollard SE Matsumoto RR
author_sort	Nguyen L
title	Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
title_short	Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
title_full	Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
title_fullStr	Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
title_full_unstemmed	Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
title_sort	off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/d5110dc8f8654002a7f54f4727ea939c
work_keys_str_mv	AT nguyenl offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview AT marshalekpj offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview AT weavercb offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview AT cramerkj offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview AT pollardse offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview AT matsumotorr offlabeluseoftransmucosalketamineasarapidactingantidepressantaretrospectivechartreview
_version_	1718396319612010496

Off-label use of transmucosal ketamine as a rapid-acting antidepressant: a retrospective chart review

Ejemplares similares